产超广谱β-内酰胺酶大肠埃希菌的目标性监测与分析

Targeted monitoring and analysis of ESBLs-positive Escherichia coli

目的了解临床产超广谱β-内酰胺酶(ESBLs)大肠埃希菌的分离和耐药性,探索产超广谱β-内酰胺酶大肠埃希菌感染病例的监控措施。方法对2010年医院临床分离的病原菌进行目标性监测,统计出产超广谱β-内酰胺酶大肠埃希菌的株数以及耐药性,并对临床产超广谱β-内酰胺酶大肠埃希菌感染病例实施监控。结果全年共分离出大肠埃希菌1879株,产超广谱β-内酰胺酶大肠埃希菌的菌株构成比为31.2%;对抗菌药物耐药率较高;全院未发生产超广谱β-内酰胺酶大肠埃希菌的暴发和流行。结论产超广谱β-内酰胺酶大肠埃希菌分离株数较多,耐药率较高,应该加强临床合理使用抗菌药物的管理,对产超广谱β-内酰胺酶大肠埃希菌感染病例实施监控,预防和减少多药耐药菌的产生,控制医院感染。

OBJECTIVE To understand the isolation and drug resistance of ESBLs-positive Escherichia coli and explore control measures of ESBLs-positive E.coli infections.METHODS Targeted monitoring of the clinical isolates of pathogenic bacteria in 2010 was performed,the drug resistance and the number of ESBLs positive E.coli were statistically analyzed,and clinical surveillance of ESBLs-positive E.coli infections was carried out.RESULTS According the result of the detection in the whole year,a total of 1879 strains of E.coli were isolated,the constituent ratio of ESBLs-positive E.coli was 31.2%;the drug resistance was high;there were no outbreak or prevalence of ESBLs-positive E.coli that occurred in the hospital.CONCLUSION There are so many strains of ESBLs-positive E.coli isolated with high drug resistance,it is necessary to enhance the clinical reasonable use of antibiotics,implement monitoring of ESBLs-positive E.coli infection so as to prevent and reduce the multidrug-resistant strains and control nosocomial infections.